MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) is projected to post its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect MaxCyte to post earnings of ($0.10) per share and revenue of $7.2840 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $6.76 million during the quarter, compared to the consensus estimate of $9.16 million. MaxCyte had a negative return on equity of 22.15% and a negative net margin of 135.14%. On average, analysts expect MaxCyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Stock Down 3.7%

Shares of MaxCyte stock traded down $0.03 during trading hours on Tuesday, reaching $0.83. 232,518 shares of the stock traded hands, compared to its average volume of 1,012,035. MaxCyte has a one year low of $0.64 and a one year high of $2.86. The company has a 50 day moving average price of $0.79 and a 200 day moving average price of $1.18. The firm has a market capitalization of $88.27 million, a price-to-earnings ratio of -1.92 and a beta of 1.37.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MXCT. Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a research report on Friday, April 24th. Craig Hallum cut their price objective on MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Finally, Wall Street Zen downgraded MaxCyte from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, MaxCyte presently has an average rating of “Hold” and a consensus price target of $5.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. bought a new position in MaxCyte in the 2nd quarter worth approximately $26,000. State of Wyoming bought a new stake in MaxCyte in the second quarter worth $38,000. BNP Paribas Financial Markets lifted its position in MaxCyte by 266.6% in the second quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock worth $57,000 after buying an additional 18,913 shares during the last quarter. Jain Global LLC bought a new stake in MaxCyte in the fourth quarter worth $45,000. Finally, Virtu Financial LLC bought a new stake in MaxCyte in the fourth quarter worth $67,000. 68.81% of the stock is currently owned by institutional investors.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical?stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical?scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.